Novo Nordisk gets NICE okay for obesity drug Wegovy
pharmaphorum
FEBRUARY 8, 2022
Novo Nordisk’s new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients than is covered by its MHRA-approved label. The 2019 Health Survey for England estimated 28% of adults in England were obese and a further 36% were overweight, according to NICE.
Let's personalize your content